66849-29-4

Usage

Chemical Properties

clear colorless liquid

InChI:InChI=1/C10H15NO/c1-9(11-7-8-12)10-5-3-2-4-6-10/h2-6,9,11-12H,7-8H2,1H3/p+1/t9-/m0/s1

Upstream product

• 2627-86-3 (S)-1-phenyl-ethylamine 
• 107-07-3 2-chloro-ethanol 
• 164219-32-3 (S)-2-oxo-2-((1-phenylethyl)amino)acetic acid 
• 540-51-2 2-bromoethanol 
• 2627-86-3 (-)-α-methylbenzylamine 
• 75-21-8 oxirane 
• 164219-31-2 ethyl (S)-2-oxo-2-((1-phenylethyl)amino)acetate 

Downstream Products

• 100596-36-9 hydrobromide (-)-N-(2-bromzethyl)-α-phenylethylamine 
• 1357081-31-2 C₁₂H₁₅NO₂ 
• 1340543-83-0 (-)-(6R,7R)-6-hydroxy-7-phenyl-4-[(S)-1-phenylethyl]-1,4-oxazepan-5-one 
• 1340544-04-8 (-)-(6S,7S)-6-hydroxy-7-phenyl-4-[(S)-1-phenylethyl]-1,4-oxazepan-5-one 
• 1340544-05-9 (-)-(6S,7S)-6-hydroxy-7-(2-nitrophenyl)-4-[(S)-1-phenylethyl]-1,4-oxazepan-5-one 
• 1340543-84-1 (-)-(6R,7R)-6-hydroxy-7-(2-nitrophenyl)-4-[(S)-1-phenylethyl]-1,4-oxazepan-5-one 
• 1340544-06-0 (-)-(6S,7S)-6-hydroxy-7-(3-nitrophenyl)-4-[(S)-1-phenylethyl]-1,4-oxazepan-5-one 
• 1340543-85-2 (-)-(6R,7R)-6-hydroxy-7-(3-nitrophenyl)-4-[(S)-1-phenylethyl]-1,4-oxazepan-5-one 
• 1340543-86-3 (-)-(6R,7R)-6-hydroxy-7-(4-nitrophenyl)-4-[(S)-1-phenylethyl]-1,4-oxazepan-5-one 
• 1340544-07-1 (-)-(6S,7S)-6-hydroxy-7-(4-nitrophenyl)-4-[(S)-1-phenylethyl]-1,4-oxazepan-5-one 
• 1340544-08-2 (-)-(6S,7S)-6-hydroxy-7-(2,6-dichlorophenyl)-4-[(S)-1-phenylethyl]-1,4-oxazepan-5-one 
• 1340543-87-4 (-)-(6R,7R)-6-hydroxy-7-(2,6-dichlorophenyl)-4-[(S)-1-phenylethyl]-1,4-oxazepan-5-one 
• 1340544-09-3 (-)-(6S,7S)-6-hydroxy-7-(3,4-dichlorophenyl)-4-[(S)-1-phenylethyl]-1,4-oxazepan-5-one 
• 1340543-88-5 (-)-(6R,7R)-6-hydroxy-7-(3,4-dichlorophenyl)-4-[(S)-1-phenylethyl]-1,4-oxazepan-5-one 

Relevant academic research and scientific papers

Chemodivergent synthesis of 7-aryl/alkyl-6-hydroxy-1,4-oxazepan-5-ones and 2-[aryl/alkyl(hydroxy)methyl]morpholin-3-ones from a common epoxyamide precursor

We present here a regiospecific synthesis of 7-alkyl- or 7-aryl-6-hydroxy-1,4-oxazepan-5-ones and 2-[aryl(hydroxy)methyl]- or 2-(1-hydroxyalkyl)morpholin-3-ones from a diastereomeric mixture of trans-3-alkyl- or -3-aryl-N-(2-hydroxyethyl)-N-(1-phenylethyl)oxirane-2- carboxamides. This chemodivergent synthesis is easily controlled by an appropriate choice of cyclization reaction conditions. Georg Thieme Verlag Stuttgart - New York.

Practical asymmetric preparation of azetidine-2-carboxylic acid

Facile and straightforward syntheses of both enantiomers of azetidine-2-carboxylic acid are described. The syntheses depart from inexpensive chemicals and allow for the production, in five to six steps, of practical quantities of each enantiomer. Synthetic highlights include the construction of the azetidine ring using an intramolecular alkylation and the use of optically active α-methylbenzylamine as chiral auxiliary.

Syntheses of morpholine-2,3-diones and 2-hydroxymorpholin-3-ones: Intermediates in the synthesis of aprepitant

The preparation of morpholine-2,3-diones and 2-hydroxymorpholin-3-ones from N-substituted β-amino alcohols is reported. These were useful intermediates in the synthesis and development of aprepitant.

Structural studies on bioactive compounds. 34.1 Design, synthesis, and biological evaluation of triazenyl-substituted pyrimethamine inhibitors of Pneumocystis carinii dihydrofolate reductase

The triazenyl-pyrimethamine derivative 3a (TAB), a potent and selective inhibitor of Pneumocystis carinii DHFR, was selected as the starting point for a lead optimization study. Molecular modeling studies, corroborated by a recent crystal structure determination of the ternary complex of P. carinii DHFR-NADPH bound to TAB, predicted that modifications to the acetoxy residue of the lead inhibitor could exploit binding opportunities in the vicinity of an active site pocket bounded by residues Ile33, Lys37, and Leu72. Substitutions in the benzyl moiety with electron-donating and electron-withdrawing groups were predicted to probe face-edge interactions with amino acid Phe69 unique to the P. carinii enzyme. New triazenes 10a-v and 12a-f were prepared by coupling the diazonium tetrafluoroborate salt 6b of aminopyrimethamine with substituted benzylamines or phenethylamines. The most potent of the new inhibitors against P. carinii DHFR was the naphthylmethyl-substituted triazene 10t (IC50: 0.053 μM), but a more substantial increase in potency against the rat liver DHFR led to a reduction in selectivity (ratio rat liver DHFR IC50/P. carinii DHFR IC50: 5.36) compared to the original lead structure 3a (ratio rat liver DHFR IC50/P. carinii DHFR IC50: 114).

Process for preparation of pyrimidine derivatives

The present invention relates to a process for preparation of 5,6-dimethyl-2-(4-fluorophenyl-amino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine represented by the following formula (I), STR1 and its acid addition salts by reacting a pyrimidi

The Use of Heterocycles for the Conformational Restriction of Biologically Active Peptoids

A series of piperazinone ring systems have been synthesized as a means of evaluating the effect of conformational restriction of high affinity non-peptide NK1, NK3 and CCK-B receptor ligands.The synthesis of the targeted heterocycles is described along with a discussion of their affinities for their respective receptor types.

DERIVATIVES OF OPTICALLY ACTIVE (1-PHENYLETHYL)AMINE IN COMPLEXES WITH LITHIUM ALUMINUM HYDRIDE FOR THE ASYMMETRIC REDUCTION OF A CARBONYL GROUP

(R)-1-Phenylethanol is formed preferentially in the reduction of acetophenone by the complexes of lithium aluminum hydride with (-)-(2-hydroxyethyl)(1-phenylethyl)amine and (-)-methyl(2-hydroxyethyl)(1-phenylmethyl)amine.